End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.96 CNY | -0.88% | -4.68% | -40.82% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.82% | 714M | - | ||
+9.99% | 115B | B+ | ||
+12.01% | 106B | B+ | ||
-3.07% | 24.69B | B+ | ||
-1.69% | 21.97B | B | ||
-4.55% | 19.27B | A- | ||
-6.90% | 17.56B | B | ||
-39.36% | 17.32B | A- | ||
+5.82% | 14.03B | C+ | ||
+33.05% | 12.13B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688382 Stock
- Ratings InventisBio Co., Limited